title: Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine.
abstract: To test whether treatment with aminoguanidine, a drug known to prevent cross-linking between glycated proteins, is effective in improving reduced erythrocyte deformability in diabetes, we studied a group (n = 6) of ALX-induced long-term (12.7 +/- 2.2 mo of hyperglycemia) diabetic New Zealand white rabbits before and after 20 wk of treatment with aminoguanidine (100 mg.kg-1 x day-1). The key findings were as follows: 1) at 12 wk of treatment with aminoguanidine, mean erythrocyte deformability normalized and remained within the normal reference range throughout the period of aminoguanidine administration; 2) 10 wk after discontinuing aminoguanidine in a subset of diabetic rabbits, mean erythrocyte deformability deteriorated by approximately 50%; 3) blood glucose and total GHb did not vary significantly during treatment with aminoguanidine nor after its discontinuation.
authors.affiliation: State University of New York Health Science Center, Brooklyn.
authors.forename: C D
authors.initials: CD
authors.lastname: Brown
authors.forename: Z H
authors.initials: ZH
authors.lastname: Zhao
authors.forename: F
authors.initials: F
authors.lastname: De Alvaro
authors.forename: S
authors.initials: S
authors.lastname: Chan
authors.forename: E A
authors.initials: EA
authors.lastname: Friedman
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006146:Guanidines / Q000627:therapeutic use*; D008297:Male; D011817:Rabbits; D012016:Reference Values; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D006146:Guanidines; C004479:pimagedine